IntuitionLabs
Book a Meeting
Back to Articles
InuitionLabs•4/4/2025•45 min read
Why Veeva Split from Salesforce: Pharma CRM Shake-Up

Why Veeva Split from Salesforce: Pharma CRM Shake-Up

Introduction

In a major industry shake-up, Veeva Systems – long known for its customer relationship management (CRM) platform in pharma and life sciences – decided to end its partnership with Salesforce and build its own CRM technology. This split marks the end of a 15+ year collaboration that dominated life sciences CRM, forcing drugmakers and biotech firms to re-evaluate their IT roadmaps. This report examines the reasons behind Veeva's decision to "divorce" Salesforce, outlines a timeline of key events from the first announcement through 2025, and analyzes the strategic implications for pharma companies. We also delve into how the split benefits and challenges Veeva's clients, drawing on commentary from industry analysts and experts.

Background: A Successful Partnership – Until It Wasn't

Veeva was founded in 2007 with a unique model: build industry-specific CRM for life sciences on top of Salesforce's cloud platform (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice) (Hello New Veeva CRM, Salesforce is Out. What you Need to Know - Assemble Studio - Web Development & Digital Production). The arrangement was mutually beneficial for years. Veeva could rapidly deliver a pharma-tailored CRM without managing its own infrastructure, while Salesforce gained a strong foothold in the pharma and biotech sector via Veeva's specialization (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud) (Veeva vs. Salesforce: Who Will Win the Cloud Pharma Battle? - Salesforce Ben). Over time, Veeva became the dominant CRM provider in life sciences, reportedly serving 47 of the top 50 pharma companies by 2019 (Veeva vs. Salesforce: Who Will Win the Cloud Pharma Battle? - Salesforce Ben) and holding roughly 80% market share in that niche (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice) (Salesforce Poaches Pharma Clients from Veeva, Signaling Industry ...). Salesforce, for its part, agreed not to directly compete in pharma CRM as long as the partnership stood, focusing instead on other domains like medical devices (MedTech) (Will It Be Happily Ever After Post Veeva-Salesforce Divorce? - Everest Group) (Will It Be Happily Ever After Post Veeva-Salesforce Divorce? - Everest Group).

Key milestones underscored the closeness of this partnership. In 2010, the companies deepened their alliance to accelerate Veeva CRM's global rollout in pharma. By 2014, Veeva and Salesforce extended their contract through 2025, with Salesforce naming Veeva its preferred worldwide partner for pharma and biotech CRM (Veeva Systems - Veeva Systems Extends salesforce.com Partnership Into 2025) (Veeva Systems - Veeva Systems Extends salesforce.com Partnership Into 2025). For Veeva, Salesforce's platform offered proven scalability, security, and reliability, allowing Veeva to focus on life sciences features rather than basic cloud infrastructure (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud) (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud). As Veeva CEO Peter Gassner said at the time, "The Salesforce1 Platform provides the ideal cloud infrastructure for our CRM product, allowing us to focus on delivering deep industry-specific applications and continuous innovation our customers require." (Veeva Systems - Veeva Systems Extends salesforce.com Partnership Into 2025).

However, as the pharma landscape evolved and Veeva expanded its own product suite (including its Veeva Vault content and data platform for R&D and compliance), tensions quietly grew under the surface. By the late 2010s, Veeva was reliant on a third-party foundation that started to feel constraining. The CRM world had also changed – new digital channels, AI-driven analytics, and big data were becoming critical, and both Veeva and Salesforce began plotting their own visions for next-generation life sciences CRM (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice) (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice). This set the stage for the eventual split.

Why Veeva Chose to Split from Salesforce

Veeva's decision to break away was driven by several strategic and technological factors. In essence, the company wanted more control and less risk as it prepared for the future of pharma CRM. Analysts note that "mounting risks and roadblocks" in the Salesforce-dependent model ultimately made "going solo" a better option for Veeva's specialized focus (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice). Key motivations included:

  1. Technological Independence: Veeva wanted to build its own cloud platform optimized for life sciences, rather than adapting to Salesforce's general-purpose architecture. This would allow tighter integration with Veeva Vault and other Veeva products, plus more control over the roadmap (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud) (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud). The company had already proven its ability to build robust cloud platforms with Vault, giving it confidence to do the same for CRM.

  2. API and Integration Control: With its own platform, Veeva could design APIs and integration points specifically for life sciences workflows, rather than working within Salesforce's constraints. This would enable better connectivity with Veeva's API ecosystem and third-party systems (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud) (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud).

In summary, Veeva's split was a proactive strategy to control its destiny. As Veeva's CRM general manager Arno Sosna explained, having CRM on Vault gives the company "the most advanced industry-specific CRM ever and an unconstrained product roadmap" going forward (Veeva Systems - Veeva Delivers Vault CRM Suite with Vault CRM Campaign Manager). The move is about de-risking the business and positioning Veeva to deliver faster innovation for its life sciences clients. But it also sets up a direct contest with its former partner.

Timeline of Key Events (2022–2025)

The journey from decision to reality has unfolded over several years. Below is a timeline of major events in the Veeva–Salesforce split, from the initial announcement through the latest developments as of 2025:

This timeline illustrates that the Veeva-Salesforce split was not a single event but a multi-year process. What began as an amicable partnership is ending in a competitive showdown, with significant planning and preparation on all sides.

Impact on Pharma and Life Sciences Clients

For pharmaceutical and biotech companies, Veeva's move off Salesforce has far-reaching implications. These organizations must weigh the benefits of Veeva's new independent CRM against the challenges and risks of migration. Below we outline the key pros and cons for life sciences companies:

Benefits: Why Staying with Veeva (Vault CRM) Could Pay Off

  • Uninterrupted Industry Focus: Veeva's sole focus is life sciences, and its new CRM is purpose-built for this industry. Clients can expect Veeva to continue delivering pharma-specific features without dilution. As Everest Group noted, Veeva can now offer a better end-to-end experience by hosting all solutions – from clinical to commercial – on a common platform (Will It Be Happily Ever After Post Veeva-Salesforce Divorce? - Everest Group). This could translate to faster innovation of features like sample management, KOL engagement, and regulatory compliance checks that generalist CRM platforms might overlook.

  • Unified Platform & Data: Companies that use other Veeva products (for content management, clinical trial management, etc.) stand to gain from having CRM on the same Vault platform. All teams work from a single data repository, enabling 360-degree visibility. Sales, medical, and marketing can collaborate more seamlessly, since customer data and content (e.g. approved marketing assets, medical inquiry info) are in one system (Veeva Systems - Veeva Delivers Vault CRM Suite with Vault CRM Campaign Manager) (Veeva Systems - Veeva Delivers Vault CRM Suite with Vault CRM Campaign Manager). This unification can improve data quality and analytics – for example, linking sales interactions with outcomes or identifying unmet needs through integrated data. It also simplifies IT architecture (fewer integrations between disparate systems).

  • Product Roadmap Control: With Veeva no longer constrained by Salesforce's development schedule or rules, clients gain more influence over the CRM's evolution. Veeva has promised an accelerated roadmap of enhancements now that it "owns" the platform (It's Not You, It's Us: Inside the Veeva vs. Salesforce Split - Ideas Exchange). Pharma customers can push for new capabilities (like advanced AI suggestions for reps or new digital engagement channels) knowing Veeva can build them natively. There's no dependency on Salesforce delivering a generic feature first. Essentially, Veeva can tailor its CRM roadmap purely based on life science customer feedback and emerging industry needs, which could mean more frequent and relevant updates for users.

  • Potential Cost Savings: While switching platforms has costs, in the long run Veeva's independence could benefit customers financially. Veeva will no longer owe Salesforce a 15% cut of CRM revenues, which opens the door for more competitive pricing or at least less upward price pressure on clients (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud). Moreover, Veeva can offer bundle deals across its suite (since all on one platform) that might be more cost-effective than piecemeal solutions. Some analysts believe owning the full stack will let Veeva optimize performance and costs, possibly passing on savings to customers or investing more in support services (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma) (Will It Be Happily Ever After Post Veeva-Salesforce Divorce? - Everest Group).

  • Data Residency & Compliance: With Vault CRM, data is hosted in Veeva's controlled cloud (likely on AWS in Veeva's chosen regions). Pharma companies dealing with strict data residency laws or GDPR requirements may appreciate the flexibility of Veeva's hosting versus being tied to Salesforce's infrastructure. Veeva can architect data handling to meet GxP and 21 CFR Part 11 regulations common in life sciences. And because Veeva is solely focused on this industry, it may be more attuned to upcoming regulatory changes (like new privacy rules) that could be built directly into the platform. Overall, customers might feel they have greater ownership and oversight of their data when it's managed by a vendor dedicated to their sector.

  • Service and Support Tailored to Pharma: Under the old model, Veeva clients sometimes had to work with both Veeva and Salesforce for certain issues (especially deep technical platform problems). Post-split, Veeva provides one-throat-to-choke support – there's no hand-off to Salesforce for platform-level fixes. Veeva also can enforce service level agreements suited to pharma's needs. Everest analysts highlight that Veeva can now leverage its own partner ecosystem to provide more personalized service in areas like data migration, validation, and training (Will It Be Happily Ever After Post Veeva-Salesforce Divorce? - Everest Group). Clients should get faster responses for issues because the entire stack is Veeva's responsibility. In theory, this could improve reliability and user satisfaction.

  • Freedom from Salesforce's Constraints: Many life sciences companies use Veeva precisely because it was the de facto standard. But they were also indirectly tied to Salesforce (e.g., needing Salesforce administrator skills, staying compatible with Salesforce updates, etc.). By moving to Vault CRM, clients free themselves from Salesforce's ecosystem requirements. They no longer need to maintain Salesforce-specific customizations or integrations, which in some cases means less overhead. Also, any concerns about Salesforce's future directions (unrelated platform changes, pricing of Force.com, etc.) are taken off the table. In a sense, customers who commit to Veeva Vault CRM are betting on a more focused, stable long-term path for their commercial operations software.

Disadvantages: Challenges & Risks of the Transition

  • Migration Complexity: Moving an entire CRM system is non-trivial, especially in a regulated industry. Pharma companies face a complex migration of data, processes, and integrations from the old Veeva (Salesforce) CRM to the new Vault CRM. Customer records, history, and multi-year data need to be transferred and validated. Any integrations with other systems (like marketing automation, data warehouses, ERP, medical information systems) have to be rebuilt or adjusted for the new platform (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma) (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma). This requires careful planning and resources. Many organizations will need to form dedicated migration teams, engage consultants, and allocate budget to execute this transition smoothly (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma). For global pharma companies with thousands of reps in the field, the data migration and cutover is a major IT project that can take many months of preparation and testing.

  • Short-Term Disruption Risks: During the transition period, there is potential for business disruption. Sales and medical teams might experience downtime or reduced functionality as systems switch over. Even with parallel running, users have to be trained on the new Vault CRM interface and features (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma). There may be a learning curve, and productivity could dip in the short run if the new system isn't tuned perfectly. Additionally, if a company is mid-launch for a new drug or executing critical sales strategies, any hiccups in CRM availability or accuracy could impact operations. Pharma firms are thus wary of a risky "big bang" switchover. Many are choosing phased migrations (e.g., one country or one business unit at a time) to mitigate this, but that prolongs the period of running two systems in parallel, which itself is challenging.

  • Compatibility and Feature Gaps: While Veeva has strived to make Vault CRM feature-complete, initial versions of any new platform may have some gaps or differences. Certain custom extensions or third-party plugins that companies built for Veeva CRM on Salesforce might not immediately exist on Vault. For example, if a company used a specific Salesforce AppExchange add-on for e-signatures or sample inventory, they'll need to see if Veeva's new platform supports it or find an alternative. Some integrations (like with Salesforce Marketing Cloud or Service Cloud) that were straightforward before may need re-working, since the underlying data model has changed (Veeva CRM Leaving Salesforce: Impact on Life Sciences Cloud) (Veeva vs. Salesforce: Who Will Win the Cloud Pharma Battle? - Salesforce Ben). Early adopters of Vault CRM have generally reported that the core functionality is equivalent, but power users could notice subtle differences that require adjustment. Until the new platform fully matures, clients face some uncertainty about whether all their use cases are met out-of-the-box.

  • Resource and Training Burden: Implementing Vault CRM isn't just a software upgrade; it can be seen as a new system deployment. Companies will need to retrain hundreds or thousands of end users (sales reps, managers, MSLs, etc.) on any UI changes and new capabilities. They also need to re-skill their CRM administrators and IT staff to learn the Vault Platform configuration and administration, which differs from Salesforce's tools. For years, many organizations have built internal expertise around Salesforce/Veeva configuration (workflow rules, custom objects, etc.); now they must invest in developing Vault CRM expertise. In the interim, companies might depend heavily on Veeva's professional services or consultants, which can be costly. Smaller biotechs with lean IT teams could feel this burden acutely.

  • Multi-Vendor Juggling (If Not Staying with Veeva): Some pharma companies might consider switching to Salesforce's new Life Sciences Cloud instead of staying with Veeva. That path has its own challenges – it essentially means adopting Salesforce (potentially with IQVIA's help) as a direct CRM vendor. Those who choose that route face a migration as well (to a different CRM entirely) and might lose the tight integration with Veeva's other suites (like Vault R&D). Conversely, companies that stick with Veeva Vault CRM will lose native compatibility with Salesforce's broader ecosystem (Salesforce apps or partners). Either choice involves trade-offs, and clients must "think through the choices, timing, and approach" carefully to set themselves up for a different future (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice). There is no zero-effort option, which makes some organizations uncomfortable. Essentially, pharma companies are forced to make a strategic CRM decision that they haven't had to make in over a decade, and this analysis itself is a significant undertaking.

  • Uncertainty in a Two-Vendor Race: Once the dust settles, clients will be relying on whichever vendor they choose (Veeva or Salesforce) to continually meet their needs. There's a risk in leaving the known for the unknown. If a company follows Veeva to Vault and for some reason Veeva struggles with this new platform, the client could face a setback. On the other hand, if they go with Salesforce's nascent Life Sciences Cloud and Salesforce doesn't invest enough (since pharma is still <1% of its revenue (One of the biggest decisions facing pharma companies right now: Veeva or… - Sandy Donaldson - 160 comments)), they could end up with a less responsive partner. In short, pharma firms are betting on vendor execution. The conservative nature of the industry makes this a notable disadvantage – many would prefer the status quo stability, but that status quo is ending. Some may hedge by delaying the decision as long as possible (using the 2030 deadline), but eventually they must commit one way or the other.

Despite these challenges, most observers believe the transition is manageable with proper planning. Veeva and Salesforce have each offered extensive support resources to help customers migrate. The five-year window (2025–2030) is purposely generous, allowing larger enterprises to transition at their own pace (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma) (Salesforce Veeva Split: Adapt for Success). As one life sciences IT blog noted, early planning – establishing internal task forces, assessing current systems, and running pilots – will be crucial to minimize risks and ensure continuity during the switch (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma) (How Will You Transition Your CRM During the Veeva – Salesforce CRM Separation? - QPharma).

Strategic Implications and Industry Reactions

The end of the Veeva-Salesforce union is reshaping the competitive landscape of pharma tech. Both companies, once close partners, are now fully pivoting to compete in the life sciences CRM arena, which has several important implications:

In terms of market impact, early signs (like Salesforce's poaching of some clients in 2024) indicate that a segment of cost-sensitive or Salesforce-loyal clients will defect, while the majority are likely to stay with Veeva at least through the first phase of the transition. Veeva itself is projecting continued growth (~18% in 2025) and not expecting a major drop-off in customers (One of the biggest decisions facing pharma companies right now: Veeva or… - Sandy Donaldson - 160 comments). This suggests confidence that it can carry its install base over to Vault CRM. Only time will tell how the "pharma CRM war" plays out, but the mere fact that such competition exists is a sea change from the previous status quo.

Conclusion

The split between Veeva and Salesforce represents a transformative moment for the pharma and life sciences IT landscape. What began as a pioneering partnership to bring cloud CRM to pharma has evolved into a competitive duel, driven by Veeva's need for autonomy and Salesforce's desire to capture a lucrative market. From the initial December 2022 breakup announcement through the product launches of 2024 and the contract's end in 2025, we have seen a carefully orchestrated transition that will continue unfolding until 2030.

For life sciences companies, this is more than a vendor switch – it's an opportunity to modernize customer engagement strategies, but also a mandate to navigate technical complexity. The benefits of Veeva's independent path – an integrated platform, potential cost savings, and a laser focus on industry innovation – are compelling. The challenges – data migration, re-training, and uncertainty – are non-trivial but surmountable with proper planning. As one expert emphasized, viewing this as "just an IT migration" would be a mistake; it is a strategic inflection point (Salesforce or Veeva: How drugmakers can navigate the upcoming CRM split - PharmaVoice). Organizations that proactively assess their options and chart a thoughtful course will be best positioned to thrive in the new CRM landscape.

In the coming years, we can expect accelerated innovation as Veeva and Salesforce compete head-to-head, each leveraging their strengths (deep industry expertise vs. broad technology prowess) to win over pharma clients. For customers, the silver lining of this split is a future with more choices and perhaps more advanced capabilities in their CRM tools than ever before. The pharma CRM of 2030 may look very different from that of 2020, thanks in large part to this "creative destruction" of an old alliance.

Ultimately, Veeva's break from Salesforce underscores a broader theme in enterprise technology: the need to balance partnership and control. Veeva decided that to serve its specialized market better, it had to control its own destiny. Pharma companies now must decide which path will best control theirs. The ripple effects of this decision will be felt across the industry for years, making it one of the most significant enterprise software shifts in recent memory.

Sources:

veevasalesforcecrmlife-sciencespharmaenterprise-softwaredigital-transformation

DISCLAIMER

The information contained in this document is provided for educational and informational purposes only. We make no representations or warranties of any kind, express or implied, about the completeness, accuracy, reliability, suitability, or availability of the information contained herein. Any reliance you place on such information is strictly at your own risk. In no event will IntuitionLabs.ai or its representatives be liable for any loss or damage including without limitation, indirect or consequential loss or damage, or any loss or damage whatsoever arising from the use of information presented in this document. This document may contain content generated with the assistance of artificial intelligence technologies. AI-generated content may contain errors, omissions, or inaccuracies. Readers are advised to independently verify any critical information before acting upon it. All product names, logos, brands, trademarks, and registered trademarks mentioned in this document are the property of their respective owners. All company, product, and service names used in this document are for identification purposes only. Use of these names, logos, trademarks, and brands does not imply endorsement by the respective trademark holders. IntuitionLabs.ai is an AI software development company specializing in helping life-science companies implement and leverage artificial intelligence solutions. Founded in 2023 by Adrien Laurent and based in San Jose, California. This document does not constitute professional or legal advice. For specific guidance related to your business needs, please consult with appropriate qualified professionals.